Aurobindo Pharma aims to become debt free in 3 years sans Sandoz deal

In September last year, the USD three billion drug maker said its US subsidiary entered into an agreement to acquire commercial operations and three manufacturing facilities in America from Sandoz Inc, USA, a Novartis Division, for USD 900 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2XFs0wt
via IFTTT